20/15 Visioneers, a premier science and technology management consultancy, announced the establishment of its New AI & Generative AI Practice. This initiative aims to enhance the efficiency and impact of AI & Generative AI in R&D, significantly reducing the operational costs.
Recognizing the essential role of computational techniques, scientific informatics, and in silico-first strategies, 20/15 Visioneers has been assisting R&D organizations since 1999. The consultancy has focused on revamping data culture, strategy, and platforms since 2019 to prepare these organizations for the AI revolution. With this new practice, 20/15 Visioneers is consolidating its expertise to provide focused, world-class AI capabilities.
“If you are not using AI or GenAI in your R&D processes today you are most likely behind, which means you are operating inefficiently and losing ground against your competitors and the industry as a whole. The longer you delay, the harder it will be to catch up”, says John F. Conway, Chief Visioneer Officer, 20/15 Visioneers.
Leading this transformative effort is Dr. Raminderpal Singh, who is appointed as the Global Head of AI & GenAI Practice. He will spearhead business development and deliver essential AI consulting and professional services to the R&D industry. With 30 years of global business and AI experience, including the commercialization of IBM Watson Genomics, Dr. Singh is well-equipped to drive this initiative forward.
“AI and Generative AI technologies have rapidly evolved in the last few years and continue to evolve. They have now reached a point where they can generate useful R&D insights at a fraction of the time versus manual approaches. However, domain knowledge and experience are required to select and implement the right technologies cost-efficiently and effectively. I am excited to lead this new practice to address this market need”, says Dr. Singh.
The launch of 20/15 Visioneers’ New AI & Generative AI Practice marks a significant advancement in the integration of cutting-edge technologies within R&D processes. As the company continues to “Visioneer” the “Lab of the Future,” its comprehensive expertise in life sciences and materials science will drive the adoption of AI and Generative AI, revolutionizing how research and development are conducted.
